Sabinsa’s Curcumin C3 Complex®, the #1 researched curcumin ingredient on the market, was used in a new published study on Non-Alcoholic Fatty Liver Disease (NAFLD), the most common chronic liver condition for which no approved pharmaceutical treatments exist.
NAFLD is a spectrum of disorders ranging from steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis of the liver. It is also commonly associated with metabolic syndrome and cardiovascular diseases. The American Liver Foundation estimates at least 25% of the US population has NAFLD.
The peer-reviewed paper published in the Journal of Cellular Biochemistry, 2019; 120: 15989-reports on the efficacy of C3 Complex combined with Sabinsa’s bioavailability enhancer BioPerine® on NAFLD subjects in a randomized controlled parallel-group clinical trial.
The decrease in the severity of NAFLD in the subjects was gauged by hepatic sonography, and significant improvement was observed in several elevated liver function parameters such as ALT, ASP, and ALP in NAFLD subjects treated with the C3 Complex and BioPerine combination. NAFLD severity was reduced in a statistically significant way in the treatment group compared to the placebo group. No adverse effect on the hematological parameters were found, showing the safety of the ingredients.
“We're encouraged by the researchers’ conclusion that combined supplementation of C3 Complex and BioPerine may provide a safe and viable method for curtailing the progress of NAFLD,” said Sabinsa founder Dr. Muhammed Majeed.
The study may be accessed here: 15996 https://doi.org/10.1002/jcb.28877.